Apellis Pharmaceuticals Stock Analysis
APLS Stock | USD 41.31 0.69 1.64% |
Apellis Pharmaceuticals is undervalued with Real Value of 48.53 and Target Price of 71.71. The main objective of Apellis Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Apellis Pharmaceuticals is worth, separate from its market price. There are two main types of Apellis Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Apellis Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Apellis Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Apellis Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Apellis Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Apellis Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Apellis Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Apellis |
Apellis Stock Analysis Notes
About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.43. Apellis Pharmaceuticals had not issued any dividends in recent years. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people. For more info on Apellis Pharmaceuticals please contact the company at 617 977 5700 or go to https://www.apellis.com.Apellis Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Apellis Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Apellis Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Apellis Pharmaceuticals generated a negative expected return over the last 90 days | |
Apellis Pharmaceuticals has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 396.59 M. Net Loss for the year was (528.63 M) with profit before overhead, payroll, taxes, and interest of 69.79 M. | |
Apellis Pharmaceuticals currently holds about 852.8 M in cash with (594.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
Apellis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Over 96.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from seekingalpha.com: Apellis Pharmaceuticals enters into senior secured credit facility |
Apellis Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Apellis Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Apellis Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
20th of February 2024 Upcoming Quarterly Report | View | |
2nd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
20th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Apellis Largest EPS Surprises
Earnings surprises can significantly impact Apellis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-05-07 | 2024-03-31 | -0.47 | -0.54 | -0.07 | 14 | ||
2018-04-30 | 2018-03-31 | -0.33 | -0.43 | -0.1 | 30 | ||
2018-03-19 | 2017-12-31 | -0.48 | -0.6 | -0.12 | 25 |
Apellis Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Apellis Pharmaceuticals' ESG score is a quantitative measure that evaluates Apellis Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Apellis Pharmaceuticals' operations that may have significant financial implications and affect Apellis Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Apellis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Apellis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apellis Pharmaceuticals backward and forwards among themselves. Apellis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Apellis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | T. Rowe Price Associates, Inc. | 2024-03-31 | 2.5 M | Fmr Inc | 2023-12-31 | 2.1 M | Assenagon Asset Management Sa | 2024-03-31 | 2 M | Boxer Capital Llc | 2024-03-31 | 1.7 M | Geode Capital Management, Llc | 2023-12-31 | 1.6 M | Artal Group S A | 2023-12-31 | 1.4 M | Pictet Asset Manangement Sa | 2023-12-31 | 1.3 M | Polar Capital Holdings Plc | 2023-12-31 | 1.1 M | Fiera Capital Corporation | 2024-03-31 | 948.4 K | Wellington Management Company Llp | 2023-12-31 | 16.4 M | Ecor1 Capital, Llc | 2023-12-31 | 11.2 M |
Apellis Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.01 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Apellis Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Apellis Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Apellis Profitablity
Apellis Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Apellis Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Apellis Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Apellis Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Apellis Pharmaceuticals' profitability requires more research than a typical breakdown of Apellis Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.8) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.36) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.36. Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.67) | (0.70) | |
Return On Capital Employed | (0.96) | (1.00) | |
Return On Assets | (0.67) | (0.70) | |
Return On Equity | (2.72) | (2.85) |
Management Efficiency
Apellis Pharmaceuticals has return on total asset (ROA) of (0.279) % which means that it has lost $0.279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2294) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2024. Return On Capital Employed is likely to drop to -1 in 2024. At this time, Apellis Pharmaceuticals' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 205.1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 18.2 M in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 1.64 | 1.95 | |
Net Current Asset Value | 0.00 | 0.00 | |
Tangible Asset Value | 0.00 | 0.00 | |
Tangible Book Value Per Share | 1.64 | 1.95 | |
Enterprise Value Over EBITDA | (13.31) | (13.98) | |
Price Book Value Ratio | 36.52 | 19.30 | |
Enterprise Value Multiple | (13.31) | (13.98) | |
Price Fair Value | 36.52 | 19.30 | |
Enterprise Value | 1.5 B | 1.6 B |
The analysis of Apellis Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Apellis Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Apellis Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.965 |
Technical Drivers
As of the 20th of May, Apellis Pharmaceuticals shows the risk adjusted performance of (0.12), and Mean Deviation of 2.54. Apellis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate thirteen technical drivers for Apellis Pharmaceuticals, which can be compared to its peers. Please confirm Apellis Pharmaceuticals market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Apellis Pharmaceuticals is priced correctly, providing market reflects its regular price of 41.31 per share. Given that Apellis Pharmaceuticals has information ratio of (0.24), we suggest you to validate Apellis Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Apellis Pharmaceuticals Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Apellis Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Apellis Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Apellis Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apellis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apellis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Apellis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Apellis Pharmaceuticals Predictive Daily Indicators
Apellis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Apellis Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Apellis Pharmaceuticals Corporate Filings
8K | 14th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 9th of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 7th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
26th of April 2024 Other Reports | ViewVerify | |
F4 | 19th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 15th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 9th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 2nd of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Apellis Pharmaceuticals Forecast Models
Apellis Pharmaceuticals' time-series forecasting models are one of many Apellis Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Apellis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Apellis Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Apellis Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Apellis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Apellis Pharmaceuticals. By using and applying Apellis Stock analysis, traders can create a robust methodology for identifying Apellis entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (1.33) | (1.39) | |
Operating Profit Margin | (1.30) | (1.37) | |
Net Loss | (1.33) | (1.40) | |
Gross Profit Margin | 0.85 | 0.99 |
Current Apellis Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Apellis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Apellis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
71.71 | Strong Buy | 17 | Odds |
Most Apellis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Apellis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Apellis Pharmaceuticals, talking to its executives and customers, or listening to Apellis conference calls.
Apellis Stock Analysis Indicators
Apellis Pharmaceuticals stock analysis indicators help investors evaluate how Apellis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Apellis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Apellis Pharmaceuticals stock analysis, traders can identify Apellis Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 553.1 M | |
Long Term Debt | 93 M | |
Common Stock Shares Outstanding | 118.7 M | |
Total Stockholder Equity | 194.5 M | |
Tax Provision | 2.1 M | |
Property Plant And Equipment Net | 21.1 M | |
Cash And Short Term Investments | 352.3 M | |
Cash | 352.3 M | |
Accounts Payable | 37.5 M | |
Net Debt | -241.4 M | |
50 Day M A | 51.4794 | |
Total Current Liabilities | 247.6 M | |
Other Operating Expenses | 913.7 M | |
Non Current Assets Total | 22.4 M | |
Non Currrent Assets Other | 1.3 M | |
Stock Based Compensation | 105.9 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apellis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Apellis Stock analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.43) | Revenue Per Share 4.333 | Quarterly Revenue Growth 2.843 | Return On Assets (0.28) | Return On Equity (1.23) |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.